Business
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial
InMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial ...
About this update from Infield Minerals Corp
[{"type":"text","content":"\n\n\n\nInMed Submits Clinical Trial Application to Evaluate INM-755 in Second Phase 1 Trial\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nVANCOUVER, March 24, 2020\n\n\n\nVANCOUVER, March 24, 2020 /CNW/ - InMed Pharmaceuticals Inc. (\"InMed\" or the \"Company\") (TSX:IN; OTCQX:IMLFF), a clinical stage pharmaceutical company developing medications targeting diseases with high unmet medical need and leading the way in the clinical development of cannabinol (CBN), today announced the filing of a Clinical Trial Application (\"CTA\") in the Netherlands to initiate a second Phase 1 human clinical trial for INM-755 in healthy volunteers. \n\n \n \n \n \n \n \n\n \n755-102-HV is a randomized, double-blind, vehicle-controlled, Phase 1 study designed to evaluate the safety and tolerability of INM-755 cream applied daily on epidermal wounds in healthy volunteers. Two strengths of INM-755 cream will be evaluated in 8 adult subjects over a 14-day treatment period. \n\"This second Phase 1 trial represents another important step towards efficacy trials with INM-755,\" said Alexandra Mancini, Senior Vice President of Clinical and Regulatory Affairs. \"The review of this CTA application will proceed as usual despite the restrictions in place in the Netherlands for the COVID-19 pandemic. Once the CTA is approved, enrollment will begin as soon as possible after those restrictions are lifted.\" \nAbout InMed: InMed Pharmaceuticals is a clinical stage pharmaceutical company developing a pipeline of cannabinoid-based medications, initially focused on the therapeutic benefits of cannabinol (CBN) in diseases with high unmet medical need. The Company is dedicated to delivering new therapeutic alternatives to patients that may benefit from cannabinoid-based medicines. For more information, visit www.inmedpharma.com.\nAbout INM-755: INM-755 is a CBN cream intended as a topical therapy to treat epidermolysis bullosa (EB) and potentially other dermatological diseases. Preclinical data demonstrate that INM-755 may help relieve hallmark EB symptoms, such as inflammation...